Genetic deletion of the H2afy gene using CRISPR/Cas9 neither reduced 9464D cell proliferation in vitro nor tumor growth in immune competent mice, but reverted in vivo resistance to PD-1 blockade (34, 35, 53). The gene discussed is MACROH2A1; the disease is neoplasm.